首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

2126435

生物標記發現服務市場：策略性洞察與預測（2026-2035）

Biomarker Discovery Services Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計生物標記發現服務市場將從 2026 年的 21.8 億美元成長到 2035 年的 63.5 億美元，複合年成長率為 12.6%。

全球生物標記發現服務市場正經歷強勁成長，這主要得益於精準醫療的廣泛應用和藥物研發日益複雜的挑戰。生物標記發現服務為製藥公司、生物技術公司、學術機構和診斷開發公司提供專業的實驗室、計算科學和轉化研究能力，以識別具有臨床意義的生物標記。現代生物標記發現不再局限於簡單的實驗室實驗，而是透過整合基因組學、蛋白質組學、代謝體學、轉錄組學、生物資訊學和人工智慧等技術的協作研究流程來實現。由於多組體學資料集需要高度專業的基礎設施和科學專長，企業內部的研究團隊常常面臨技術和分析的限制。因此，外包服務使企業能夠利用最尖端科技，同時提高研究效率並降低營運複雜性。隨著精準醫療在腫瘤學、神經病學、免疫學、心血管疾病、感染疾病和罕見遺傳疾病等領域的不斷擴展，市場需求也持續成長。在整個藥物研發過程中，治療藥物的開發越來越依賴能夠改善患者分層、疾病監測和臨床終點選擇的生物標記。服務供應商持續投資於高通量定序、蛋白質組學平台、數位病理學和先進的生物資訊技術，以改善生物標記的識別並加速科學檢驗。生物標記發現服務的策略重要性不僅限於研究，還延伸至伴隨診斷開發、精準治療、臨床試驗最佳化和個人化醫療等領域。

市場促進因素

擴大精準醫療和標靶治療

精準醫療越來越依賴生物標記來識別適合標靶治療的患者群體，這使得生物標記的發現成為藥物創新不可或缺的一部分。由於製藥公司需要涵蓋分子生物學、生物資訊學、實驗科學和轉化醫學等跨學科領域的專業知識，因此對專業服務供應商的需求正在轉向。企業內部的研究能力往往難以在維持科學研究效率的同時，管理日益複雜的多組體學專案。生物標記發現機構正在擴展其綜合實驗室和計算能力，以加速生物標記的鑑定並支持臨床開發。這種轉變正在增強對生物標記發現外包服務的長期需求。

多體學研究的廣泛應用

現代藥物研發日益整合基因組學、蛋白質組學、轉錄組學、代謝體學和表觀基因，以增進對生物學的理解並促進治療藥物的開發。由於單一分子資料集往往無法全面反映疾病的複雜性，因此需要整合的分析方法才能發現有意義的生物標記物，而這類方法的需求正在不斷成長。製藥公司擴大與擁有先進定序平台、質譜技術和計算生物學專業知識的專業服務供應商合作。體學技術、人工智慧和基於雲端的分析技術，以增強科學解讀並縮短發現時間。這些技術進步正在推動整個生物標記發現服務市場持續成長的需求。

生物標記檢驗的複雜性日益增加。

在生物標記開發過程中，在支持療法開發或監管申報之前，廣泛的分析檢驗、臨床相關性分析和統計學評估變得越來越重要。隨著現代生物標記通常涉及多個分子路徑、大規模的基因組資料集和複雜的計算分析，檢驗的複雜性也不斷增加。製藥公司正與專業的藥物研發機構合作，這些機構能夠將實驗室檢驗、生物資訊學和轉化醫學整合到協調的開發項目中。服務供應商也不斷提升自身的研究能力，以提高生物標記的可靠性，同時支援日益複雜的精準醫療應用。這種發展趨勢正在推動外包生物標記藥物研發服務的持續擴張。

生物標記整合在整個藥物開發過程中的進展

生物標記在整個藥物研發過程中，對標靶識別、受試者招募、劑量最佳化、臨床終點選擇以及上市後治療監測的影響日益增強。隨著精準醫療策略提高臨床試驗效率和治療成功率，製藥公司不斷拓展其生物標記計畫。因此，生物標記發現不再是孤立的研究功能，而是貫穿藥物整個生命週期的基礎性活動。服務供應商正將生物標記鑑定、計算生物學、轉化研究和伴隨診斷開發整合到綜合科學項目中，從而加強研發與臨床開發之間的合作。這種整合的研究模式將持續推動市場成長。

市場限制因素

多組體學分析和生物標記檢驗所涉及的高度科學複雜性持續導致研究成本增加和技術挑戰。不同生物標記平台缺乏標準化的調查方法，持續造成臨床應用和監管核准的延誤。對專有生物數據、基因組資訊和智慧財產權的保護，持續影響製藥和生技公司外包決策。

按服務類型
- 生物標記鑑定
- 生物標記檢驗
- 多體學資料分析
- 生物資訊學和數據分析
- 檢體處理和生物銀行
- 伴隨生物標記的開發
- 其他生物標記發現服務
依生物標誌類型
- 基因生物標記
- 蛋白質體學生物標記
- 代謝體學物標誌物
- 轉錄組生物標記
- 表觀遺傳生物標記
- 影像生物標記
- 其他類型的生物標記
最終用戶
- 製藥和生物技術公司
- 學術研究機構
- 受託研究機構（CRO）
- 診斷公司

第10章：生物標記發現服務市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：生物標記發現服務市場：國別分析

美國
加拿大
德國
英國
法國
義大利
中國
日本
韓國
印度
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
服務啟動

第13章：公司簡介

Thermo Fisher Scientific Inc.
Eurofins Scientific SE
Charles River Laboratories International, Inc.
Labcorp Drug Development
IQVIA Inc.
Precision for Medicine
BioAgilytix Labs, LLC
Frontage Laboratories, Inc.
Medpace Holdings, Inc.
WuXi AppTec Co., Ltd.
Evotec SE
ICON plc
Q2 Solutions（IQVIA）
SGS SA
Revvity, Inc.

第14章：生物標記發現服務市場：商業預測分析

依生物標記類型進行預測
- 基因生物標記
- 蛋白質體學生物標記
- 轉錄組生物標記
- 代謝組學生物標記
最終用戶的預測
- 製藥和生物技術公司
- 學術研究機構
- 診斷相關企業

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009153

The Biomarker Discovery Services Market is forecast to grow at a CAGR of 12.6%, reaching USD 6.35 billion in 2035 from USD 2.18 billion in 2026.

The global biomarker discovery services market is experiencing robust growth, driven by the expanding precision medicine landscape and the increasing complexity of therapeutic development. Biomarker discovery services provide specialized laboratory, computational, and translational research capabilities that enable pharmaceutical companies, biotechnology organizations, academic institutions, and diagnostic developers to identify clinically meaningful biological markers. Modern biomarker discovery extends beyond laboratory experimentation by integrating genomics, proteomics, metabolomics, transcriptomics, bioinformatics, and artificial intelligence into coordinated research workflows. Internal research teams frequently encounter technological and analytical limitations because multi-omics datasets require highly specialized infrastructure and scientific expertise. Outsourcing therefore enables organizations to access advanced technologies while improving research efficiency and reducing operational complexity. Demand is increasing because precision medicine continues expanding across oncology, neurology, immunology, cardiovascular diseases, infectious diseases, and rare genetic disorders. Therapeutic development increasingly depends on biomarkers capable of improving patient stratification, disease monitoring, and clinical endpoint selection throughout drug development. Service providers continue investing in high-throughput sequencing, proteomics platforms, digital pathology, and advanced bioinformatics that improve biomarker identification while accelerating scientific validation. The strategic importance of biomarker discovery services extends beyond research into companion diagnostic development, precision therapeutics, clinical trial optimization, and personalized healthcare.

Market Drivers

Expanding Precision Medicine and Targeted Therapeutics

Precision medicine increasingly depends on biomarkers that identify appropriate patient populations for targeted therapies, making biomarker discovery an essential component of pharmaceutical innovation. Demand is shifting toward specialized service providers because pharmaceutical companies require multidisciplinary expertise spanning molecular biology, bioinformatics, laboratory science, and translational medicine. Internal research capabilities frequently struggle to manage increasingly sophisticated multi-omics programs while maintaining scientific efficiency. Biomarker discovery organizations are expanding integrated laboratory and computational capabilities that accelerate biomarker identification while supporting clinical development. This transition strengthens long-term demand for outsourced biomarker discovery services.

Increasing Adoption of Multi-Omics Research

Modern drug discovery increasingly integrates genomics, proteomics, transcriptomics, metabolomics, and epigenomics to improve biological understanding and therapeutic development. Demand is increasing because individual molecular datasets frequently fail to capture disease complexity, requiring integrated analytical approaches for meaningful biomarker discovery. Pharmaceutical organizations increasingly collaborate with specialized service providers possessing advanced sequencing platforms, mass spectrometry technologies, and computational biology expertise. Biomarker discovery companies continue investing in multi-omics technologies, artificial intelligence, and cloud-based analytics that strengthen scientific interpretation while reducing discovery timelines. These technological advances reinforce sustained demand across the biomarker discovery services market.

Growing Complexity of Biomarker Validation

Biomarker development increasingly requires extensive analytical validation, clinical correlation, and statistical evaluation before supporting therapeutic development or regulatory submissions. Validation complexity continues increasing because modern biomarkers frequently involve multiple molecular pathways, large-scale genomic datasets, and sophisticated computational analysis. Pharmaceutical companies are partnering with specialized discovery organizations capable of integrating laboratory validation, bioinformatics, and translational medicine into coordinated development programs. Service providers continue strengthening scientific capabilities that improve biomarker reliability while supporting increasingly advanced precision medicine applications. This evolution supports continued expansion of outsourced biomarker discovery services.

Rising Biomarker Integration Throughout Drug Development

Biomarkers increasingly influence target identification, patient recruitment, dose optimization, clinical endpoint selection, and post-market therapeutic monitoring throughout pharmaceutical development. Drug developers continue expanding biomarker programs because precision medicine strategies improve clinical trial efficiency and therapeutic success. Biomarker discovery therefore becomes a foundational activity throughout the pharmaceutical lifecycle rather than an isolated research function. Service providers are integrating biomarker identification, computational biology, translational research, and companion diagnostic development into comprehensive scientific programs that improve coordination between research and clinical development. This integrated research model continues strengthening market growth.

Market Restraints

High scientific complexity associated with multi-omics analysis and biomarker validation continues increasing research costs and technical challenges. Limited availability of standardized validation methodologies across diverse biomarker platforms continues slowing clinical translation and regulatory acceptance. Protection of proprietary biological data, genomic information, and intellectual property continues influencing outsourcing decisions among pharmaceutical and biotechnology companies.

Technology and Segment Insights

By Service Type

Biomarker Identification, Biomarker Validation, Multi-Omics Data Analysis, Bioinformatics & Data Interpretation, Sample Processing & Biobanking, Companion Biomarker Development, and Other Biomarker Discovery Services collectively define the service landscape. Biomarker identification establishes candidate molecules, while validation confirms their analytical and clinical relevance before pharmaceutical or diagnostic application. Demand is increasing for integrated service models because pharmaceutical companies seek partners capable of combining laboratory science, computational biology, and translational research within unified discovery programs. Bioinformatics, multi-omics analytics, and companion biomarker development continue becoming increasingly important as precision medicine expands across therapeutic areas.

By Biomarker Type

Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Transcriptomic Biomarkers, Epigenetic Biomarkers, Imaging Biomarkers, and Other Biomarker Types represent the primary scientific categories supporting precision medicine. Genomic and proteomic biomarkers continue generating substantial demand because targeted therapeutics increasingly depend on molecular characterization and patient stratification. Transcriptomic, metabolomic, and epigenetic biomarkers are becoming increasingly important as multi-omics research improves understanding of disease biology and treatment response. Imaging biomarkers continue expanding across oncology, neurology, and cardiovascular research where non-invasive disease monitoring supports clinical decision-making.

By End User

Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), and Diagnostic Companies each represent important sources of demand. Pharmaceutical companies increasingly outsource biomarker research because precision medicine programs require specialized laboratory technologies, computational biology expertise, and translational research capabilities. Academic institutions continue collaborating with service providers to accelerate translation of scientific discoveries into clinically meaningful biomarkers. CROs increasingly integrate biomarker discovery into broader pharmaceutical development programs supporting targeted therapeutics and companion diagnostics. Diagnostic companies continue investing in biomarker discovery to strengthen next-generation diagnostic products and personalized healthcare solutions.

Competitive and Strategic Outlook

The competitive landscape features major life science and clinical research organizations. Thermo Fisher Scientific Inc. distinguishes itself through its comprehensive portfolio of life science technologies, analytical instruments, genomics platforms, and bioinformatics capabilities. Eurofins Scientific SE distinguishes itself through one of the world's largest laboratory networks supporting genomics, proteomics, and translational research. Charles River Laboratories International, Inc. distinguishes itself through its comprehensive translational research, biomarker discovery, and preclinical development expertise. Labcorp Drug Development distinguishes itself through its integrated laboratory sciences, central laboratory services, and clinical development capabilities. IQVIA Inc. distinguishes itself through its integration of clinical research, real-world evidence, and precision medicine capabilities. Precision for Medicine distinguishes itself through its exclusive focus on precision medicine, translational research, and companion biomarker development.
Strategic developments include increasing integration of artificial intelligence and machine learning, expansion of multi-omics platforms, and growth of translational research collaborations. Companies are forming partnerships with pharmaceutical developers, academic institutions, and biotechnology firms to accelerate biomarker validation and commercialization. Service expansions focus on next-generation sequencing, high-resolution mass spectrometry, digital pathology, and cloud-enabled bioinformatics. Companies that successfully integrate laboratory science, computational analytics, translational medicine, and regulatory expertise within scalable global platforms are expected to lead the market.

Conclusion

The biomarker discovery services market is poised for significant growth, driven by the expansion of precision medicine, multi-omics research, and pharmaceutical investment in biomarker-guided drug development. The evolution from isolated laboratory research toward integrated scientific platforms supporting the complete precision medicine ecosystem is reshaping the market. Companies that successfully deliver comprehensive, scalable, and clinically meaningful biomarker discovery solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding translational research infrastructure will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Biomarker Discovery Services Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Biomarker Discovery Workflow
3.8 Biomarker Validation Landscape
3.9 Precision Medicine and Companion Diagnostics Landscape
3.10 Translational Research Trends

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Technologies
6.2 Service Innovation
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 AI Integration in Biomarker Discovery
6.6 Multi-Omics Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Biomarker Qualification Pathways
7.3 Compliance Requirements

8. Biomarker Discovery Services Market Landscape Analysis

8.1 Analysis by Biomarker Type
8.2 Analysis by Technology Platform
8.3 Analysis by Discovery Stage
8.4 Analysis by Therapeutic Area
8.5 Analysis by Sample Type

9. Biomarker Discovery Services Market Segment Analysis (2021-2035)

9.1 By Service Type
- 9.1.1 Biomarker Identification
- 9.1.2 Biomarker Validation
- 9.1.3 Multi-Omics Data Analysis
- 9.1.4 Bioinformatics & Data Interpretation
- 9.1.5 Sample Processing & Biobanking
- 9.1.6 Companion Biomarker Development
- 9.1.7 Other Biomarker Discovery Services
9.2 By Biomarker Type
- 9.2.1 Genomic Biomarkers
- 9.2.2 Proteomic Biomarkers
- 9.2.3 Metabolomic Biomarkers
- 9.2.4 Transcriptomic Biomarkers
- 9.2.5 Epigenetic Biomarkers
- 9.2.6 Imaging Biomarkers
- 9.2.7 Other Biomarker Types
9.3 By End User
- 9.3.1 Pharmaceutical & Biotechnology Companies
- 9.3.2 Academic & Research Institutes
- 9.3.3 Contract Research Organizations (CROs)
- 9.3.4 Diagnostic Companies

10. Biomarker Discovery Services Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Biomarker Discovery Services Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 China
11.8 Japan
11.9 South Korea
11.10 India
11.11 Australia
11.12 Brazil
11.13 Saudi Arabia

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Service Launches

13. Company Profiles

13.1 Thermo Fisher Scientific Inc.
13.2 Eurofins Scientific SE
13.3 Charles River Laboratories International, Inc.
13.4 Labcorp Drug Development
13.5 IQVIA Inc.
13.6 Precision for Medicine
13.7 BioAgilytix Labs, LLC
13.8 Frontage Laboratories, Inc.
13.9 Medpace Holdings, Inc.
13.10 WuXi AppTec Co., Ltd.
13.11 Evotec SE
13.12 ICON plc
13.13 Q2 Solutions (IQVIA)
13.14 SGS SA
13.15 Revvity, Inc.

14. Biomarker Discovery Services Market Commercial Forecast Analysis

14.1 Forecast by Service Type
- 14.1.1 Biomarker Identification
- 14.1.2 Biomarker Validation
- 14.1.3 Multi-Omics Data Analysis
- 14.1.4 Companion Biomarker Development
14.2 Forecast by Biomarker Type
- 14.2.1 Genomic Biomarkers
- 14.2.2 Proteomic Biomarkers
- 14.2.3 Transcriptomic Biomarkers
- 14.2.4 Metabolomic Biomarkers
14.3 Forecast by End User
- 14.3.1 Pharmaceutical & Biotechnology Companies
- 14.3.2 Academic & Research Institutes
- 14.3.3 Diagnostic Companies